Posted inBiotechnology
Posted inBiotechnology
Cash-strapped Viracta ends phase 2 study of lead cancer drug as it mulls remaining options
Cash-strapped Viracta Therapeutics is continuing to reduce its options in order to stay afloat. Less than two months after announcing…


















